WO2022266467A3 - Recombinant histone polypeptide and uses thereof - Google Patents

Recombinant histone polypeptide and uses thereof Download PDF

Info

Publication number
WO2022266467A3
WO2022266467A3 PCT/US2022/034035 US2022034035W WO2022266467A3 WO 2022266467 A3 WO2022266467 A3 WO 2022266467A3 US 2022034035 W US2022034035 W US 2022034035W WO 2022266467 A3 WO2022266467 A3 WO 2022266467A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant histone
histone polypeptide
recombinant
polypeptide
same
Prior art date
Application number
PCT/US2022/034035
Other languages
French (fr)
Other versions
WO2022266467A2 (en
Inventor
William G. Kaelin Jr.
Parker SULKOWSKI
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Publication of WO2022266467A2 publication Critical patent/WO2022266467A2/en
Publication of WO2022266467A3 publication Critical patent/WO2022266467A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to isolated or recombinant histone polypeptides and fragments thereof, compositions comprising the same, and methods for using the same to deliver macromolecules to a cell.
PCT/US2022/034035 2021-06-17 2022-06-17 Recombinant histone polypeptide and uses thereof WO2022266467A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163212071P 2021-06-17 2021-06-17
US63/212,071 2021-06-17
US202163215938P 2021-06-28 2021-06-28
US63/215,938 2021-06-28

Publications (2)

Publication Number Publication Date
WO2022266467A2 WO2022266467A2 (en) 2022-12-22
WO2022266467A3 true WO2022266467A3 (en) 2023-01-26

Family

ID=82786271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/034035 WO2022266467A2 (en) 2021-06-17 2022-06-17 Recombinant histone polypeptide and uses thereof

Country Status (1)

Country Link
WO (1) WO2022266467A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086273A2 (en) * 2002-04-08 2003-10-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone conjugates and uses thereof
WO2015184258A1 (en) * 2014-05-30 2015-12-03 The Johns Hopkins University Genetically encoded histone reporter allele constructs
WO2019173565A1 (en) * 2018-03-07 2019-09-12 Epicypher, Inc. Peptide ligase-mediated engineering of recombinant nucleosomes
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
WO2019219721A1 (en) * 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Targeted intracellular delivery of large nucleic acids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DE69828287T2 (en) 1997-06-13 2005-12-15 Gryphon Therapeutics, Inc., South San Francisco SOLID PHASE NATIVE CHEMICAL LIGATION OF UNPROTECTED OR N-CYSTEIN PROTECTED PEPTIDES IN AQUEOUS SOLUTIONS
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2343072T3 (en) 1999-01-14 2010-07-22 Amylin Pharmaceuticals, Inc. EXENDINA FOR THE SUPPRESSION OF GLUCAGON.
JP2005507870A (en) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア Low toxicity interleukin-2 mutant
MXPA04005266A (en) 2001-12-04 2004-10-11 Merck Patent Gmbh Immunocytokines with modulated selectivity.
US20070238669A1 (en) 2006-01-11 2007-10-11 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
EA200870575A1 (en) 2006-05-26 2009-08-28 Амилин Фармасьютикалз, Инк. COMPOSITIONS AND METHODS OF TREATMENT OF CONSTITUAL HEART FAILURE
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US8231706B2 (en) 2006-09-20 2012-07-31 Mt-Biomethan Gmbh Method and device for separating methane and carbon dioxide from biogas
JP2008169195A (en) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulinotopic peptide drug combo using carrier material
JP2009019027A (en) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
EP3075745B1 (en) 2011-02-10 2018-09-05 Roche Glycart AG Mutant interleukin-2 polypeptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086273A2 (en) * 2002-04-08 2003-10-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone conjugates and uses thereof
WO2015184258A1 (en) * 2014-05-30 2015-12-03 The Johns Hopkins University Genetically encoded histone reporter allele constructs
WO2019173565A1 (en) * 2018-03-07 2019-09-12 Epicypher, Inc. Peptide ligase-mediated engineering of recombinant nucleosomes
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
WO2019219721A1 (en) * 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Targeted intracellular delivery of large nucleic acids

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAN HAOBO ET AL: "A comprehensive review on histone-mediated transfection for gene therapy", BIOTECHNOLOGY ADVANCES., vol. 37, no. 1, 1 January 2019 (2019-01-01), GB, pages 132 - 144, XP055970690, ISSN: 0734-9750, DOI: 10.1016/j.biotechadv.2018.11.009 *
HARITON-GAZAL ELANA ET AL: "Direct translocation of histone molecules across cell membranes", JOURNAL OF CELL SCIENCE, COMPANY OF BIOLOGISTS LIMITED, CAMBRIDGE, vol. 116, no. 22, 15 November 2003 (2003-11-15), pages 4577 - 4586, XP002393811, ISSN: 0021-9533, DOI: 10.1242/JCS.00757 *
RYSER H J ET AL: "Histones and basic polyamino acids stimulate the uptake of albumin by tumor cells in culture", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 150, no. 695, 22 October 1965 (1965-10-22), pages 501 - 503, XP002444633, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.150.3695.501 *

Also Published As

Publication number Publication date
WO2022266467A2 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
WO2020247843A3 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
WO2019191633A3 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2017151940A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
MX2021014007A (en) EpCAM BINDING PROTEINS AND METHODS OF USE.
WO2019173692A3 (en) Anti-cd73 antibodies and methods of use thereof
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
MX2017016105A (en) Adenovirus polynucleotides and polypeptides.
WO2020061229A3 (en) Arc-based capsids and uses thereof
WO2020008377A3 (en) Ionic self-assembling peptides
IL290598A (en) Modified interleukin 2 (il-2) polypeptides, conjugates and uses thereof
MX2019006515A (en) Compositions comprising peptide wkdeagkplvk.
EP3988653A3 (en) Udp-glycosyltransferases from solanum lycopersicum
WO2021194826A3 (en) Recombinant sars-cov-2 spike protein and uses thereof
WO2005074626A3 (en) Compositions, methods and uses for a novel family of peptides
MX2020013296A (en) Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof.
WO2014165277A3 (en) POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2021198706A3 (en) Coronavirus vaccines
MX2022005676A (en) Barcoded xten polypeptides and compositions thereof, and methods for making and using the same.
MX2021014856A (en) Tgf-beta vaccine.
EP3909975A4 (en) Novel polypeptide and therapeutic uses thereof
WO2022266467A3 (en) Recombinant histone polypeptide and uses thereof
IL312744A (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
MX2023009995A (en) Compositions including sbi adjuvants and methods of use thereof.
EP4037665A4 (en) Compositions comprising pedf-derived short peptides (pdsp) and uses thereof
WO2021150713A3 (en) Human immunogenic epitopes of h, k, and e human endogenous retroviruses (hervs)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22750934

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22750934

Country of ref document: EP

Kind code of ref document: A2